Purpose Radical changes in both expression and glycosylation pattern of transmembrane mucins have been observed in various malignancies. We and others have shown that MUC1 and MUC4, two transmembrane mucins, play a sentinel role in cell signaling events that drive several epithelial malignancies. In the present study, we investigated the expression profile of MUC1 and MUC4 in the non-neoplastic bladder urothelium, in various malignant neoplasms of bladder and in bladder carcinoma cell lines. Material and Methods Immunohistochemistry was performed on tissue sections from the urinary bladder biopsies, resection samples and tissue microarrays (TMAs) with monoclonal antibodies specific for MUC1 and MUC4. We also investigated their expression in bladder carcinoma cell lines by RT-PCR and immunoblotting. Results MUC1 is expressed on the apical surface or in umbrella cells of the normal non-neoplastic bladder urothelium. Strong expression of MUC1 was also observed in urothelial carcinoma (UC). MUC1 staining increased from normal urothelium (n = 27, 0.35±0.12) to urothelial carcinoma (UC, n = 323, H-score, 2.4±0.22, p≤0.0001). In contrast to MUC1, MUC4 was expressed in all the layers of non-neoplastic bladder urothelium (n = 14, 2.5±0.28), both in the cell membrane and cytoplasm. In comparison to non-neoplastic urothelium, the loss of MUC4 expression was observed during urothelial carcinoma (n = 211, 0.56±0.06). However, re-expression of MUC4 was observed in a subset of metastatic cases of urothelial carcinoma (mean H-score 0.734±0.9). Conclusion The expression of MUC1 is increased while that of MUC4 decreased in UC compared to the normal non-neoplastic urothelium. Expression of both MUC1 and MUC4, however, are significantly higher in urothelial carcinoma metastatic cases compared to localized UC. These results suggest differential expression of MUC1 and MUC4 during development and progression of bladder carcinoma.
References
[1]
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30. doi: 10.3322/caac.21166
[2]
Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60: 244–272. doi: 10.3322/caac.20077
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, et al. (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23: 6533–6539. doi: 10.1200/jco.2005.05.516
[5]
Hauber HP, Foley SC, Hamid Q (2006) Mucin overproduction in chronic inflammatory lung disease. Can Respir J 13: 327–335.
[6]
Park HU, Kim JW, Kim GE, Bae HI, Crawley SC, et al. (2003) Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas 26: e48–e54. doi: 10.1097/00006676-200304000-00022
[7]
Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, et al. (2006) Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate 66: 421–429. doi: 10.1002/pros.20372
[8]
Voynow JA, Rubin BK (2009) Mucins, mucus, and sputum. Chest 135: 505–512. doi: 10.1378/chest.08-0412
[9]
Rachagani S, Torres MP, Moniaux N, Batra SK (2009) Current status of mucins in the diagnosis and therapy of cancer. Biofactors 35: 509–527. doi: 10.1002/biof.64
[10]
Kaur S, Sharma N, Krishn SR, Lakshmanan I, Baine MJ, et al.. (2013) MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-kappaB signaling in pancreatic cancer. Clin Cancer Res.
[11]
Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, et al. (2007) MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res 5: 309–320. doi: 10.1158/1541-7786.mcr-06-0353
[12]
Bafna S, Kaur S, Batra SK (2010) Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 29: 2893–2904. doi: 10.1038/onc.2010.87
[13]
Inata J, Hattori N, Yokoyama A, Ohshimo S, Doi M, et al. (2007) Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer 120: 2643–2649. doi: 10.1002/ijc.22613
[14]
Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, et al. (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23: 5739–5747. doi: 10.1038/sj.onc.1207713
[15]
Abd Elazeez TA, El-Balshy A, Khalil MM, El-Tabye MM, Abdul-Halim H (2011) Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. Urol Ann 3: 8–13. doi: 10.4103/0974-7796.75857
[16]
Patriarca C, Colombo P, Pio TA, Wesseling J, Franchi G, et al. (2009) Cell discohesion and multifocality of carcinoma in situ of the bladder: new insight from the adhesion molecule profile (e-cadherin, Ep-CAM, and MUC1). Int J Surg Pathol 17: 99–106. doi: 10.1177/1066896908326918
[17]
Simms MS, Hughes OD, Limb M, Price MR, Bishop MC (1999) MUC1 mucin as a tumour marker in bladder cancer. BJU Int 84: 350–352. doi: 10.1046/j.1464-410x.1999.00150.x
[18]
Xiang ST, Zhou SW, Guan W, Liu JH, Ye ZQ (2005) [Expression of MUC1 and distribution of tumor-infiltrating dentritic cells in human bladder transitional cell carcinoma]. Di Yi Jun Yi Da Xue Xue Bao 25: 1114–1118.
[19]
Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, et al. (2004) Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem 52: 253–261. doi: 10.1177/002215540405200213
[20]
Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, et al. (2004) Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem 52: 253–261. doi: 10.1177/002215540405200213
[21]
Patton S, Gendler SJ, Spicer AP (1995) The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241: 407–423. doi: 10.1016/0304-4157(95)00014-3
[22]
Hattrup CL, Gendler SJ (2008) Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70: 431–457. doi: 10.1146/annurev.physiol.70.113006.100659
[23]
Singh AP, Chaturvedi P, Batra SK (2007) Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 67: 433–436. doi: 10.1158/0008-5472.can-06-3114
[24]
Kawano T, Ahmad R, Nogi H, Agata N, Anderson K, et al. (2008) MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol 33: 153–159. doi: 10.3892/ijo.33.1.153
[25]
Li Y, Liu D, Chen D, Kharbanda S, Kufe D (2003) Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22: 6107–6110. doi: 10.1038/sj.onc.1206732
[26]
Nassar H, Pansare V, Zhang H, Che M, Sakr W, et al. (2004) Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol 17: 1045–1050. doi: 10.1038/modpathol.3800166
[27]
McDermott KM, Crocker PR, Harris A, Burdick MD, Hinoda Y, et al. (2001) Overexpression of MUC1 reconFig.ures the binding properties of tumor cells. Int J Cancer 94: 783–791. doi: 10.1002/ijc.1554
